Literature DB >> 987827

Responses to cinvristine in refractory idiopathic thrombocytopenic purpura.

I E Burton, B E Roberts, J A Child, D A Montgomery, C G Raper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 987827      PMCID： PMC1688471          DOI： 10.1136/bmj.2.6041.918

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  2 in total

1.  STUDIES ON THE SUPPRESSION OF IMMUNE RESPONSES BY THE PERIWINKLE ALKALOIDS VINCRISTINE AND VINBLASTINE.

Authors:  A C AISENBERG; B WILES
Journal:  J Clin Invest       Date:  1964-12       Impact factor: 14.808

2.  Periwinkle alkaloids and the platelet-count.

Authors:  J H Robertson; G M McCarthy
Journal:  Lancet       Date:  1969-08-16       Impact factor: 79.321
  2 in total
  4 in total

1.  Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients.

Authors:  F Cervantes; E Montserrat; C Rozman; C Diumenjo; E Feliu; A Grañena
Journal:  Postgrad Med J       Date:  1980-10       Impact factor: 2.401

2.  Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases.

Authors:  P Fenaux; I Quiquandon; M T Caulier; M Simon; M P Walter; F Bauters
Journal:  Blut       Date:  1990-04

3.  [Vincristin-therapy of chronic refractory idiopathic thrombocytopenic purpura (author's transl)].

Authors:  G Zeile
Journal:  Blut       Date:  1978-04-20

4.  Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study.

Authors:  Young Hoon Park; Hyeon Gyu Yi; Moon Hee Lee; Chul Soo Kim; Joo Han Lim
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.